Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer

[21] Ruth K(2008)Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778-172

[22] Sigurdson ER(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-614

[23] Smith EC(2014)Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG (Alliance) Z1071 Prospective Multicenter Clinical Trial Ann Surg 260 608-601

[24] Ziogas A(2018)The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB) Ann Surg 268 591-1804

[25] Anton-Culver H(2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 1796-1486

[26] Eaglehouse YL(2016)Neoadjuvant endocrine therapy for estrogen-receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-110

[27] Georg MW(2019)a brief summary of the consensus discussion on the optimal primary breast cancer treatment Breast Care 2019 103-52

[28] Shriver CD(2016)Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Ecancermedicalscience 10 609-118

[29] Solomon M(1995)Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes The British journal of social psychology 34 33-35

[30] Cochrane CT(2012)The Andersen Model of Total Patient Delay: a systematic review of its application in cancer diagnosis J Health Serv Res Policy 17 110-381

[21] Ruth K(2008)Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 J Clin Oncol 26 778-172

[22] Sigurdson ER(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-614

[23] Smith EC(2014)Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG (Alliance) Z1071 Prospective Multicenter Clinical Trial Ann Surg 260 608-601

[24] Ziogas A(2018)The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB) Ann Surg 268 591-1804

[25] Anton-Culver H(2012)Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 1796-1486

[26] Eaglehouse YL(2016)Neoadjuvant endocrine therapy for estrogen-receptor-positive breast cancer: a systematic review and meta-analysis JAMA Oncol 2 1477-110

[27] Georg MW(2019)a brief summary of the consensus discussion on the optimal primary breast cancer treatment Breast Care 2019 103-52

[28] Shriver CD(2016)Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives Ecancermedicalscience 10 609-118

[29] Solomon M(1995)Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes The British journal of social psychology 34 33-35

[30] Cochrane CT(2012)The Andersen Model of Total Patient Delay: a systematic review of its application in cancer diagnosis J Health Serv Res Policy 17 110-381